To gain insight into the mechanism(s) responsible for the superior antileukemic activity of the idasanutlin-navitoclax combination, we first investigated p53 signaling pathway activation using three high-risk B-ALL PDX samples. The gene discussed is TP53; the disease is acute lymphoblastic leukemia.